NASD · Healthcare · Diagnostics & Research · USA
Veracyte Inc is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
Veracyte is a global diagnostics company offering molecular tests to help clinicians make cancer diagnosis and treatment decisions. In the United States, it provides laboratory-developed tests through CLIA-certified labs for prostate, thyroid, breast, and bladder cancers. Outside the United States, it distributes in vitro diagnostic tests to hospitals and laboratories.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Veracyte Inc stock.
Overvalued: intrinsic value $30.19 per share, market price $43.80, margin of safety -45.1% (as of 2026-10-19).
Discounting its cash flows at 13.4% (average of 3 methods) values the shares at $30.19; the price of $43.80 is 45% above that value, and 64% of that value comes from beyond year five.
Leak Score: 59/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
VCYT is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 13.4% (average of 3 methods) values the shares at $30.19; the price of $43.80 is 45% above that value, and 64% of that value comes from beyond year five.
$30.19 per share (as of the 2026-10-19 close), against a market price of $43.80. That is a margin of safety of -45.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
59 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.